Berlin

• A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxeta … Recruiting
  2024-512338-13-00 3 2024-11-11 Metastatic Castration-Resistant Prostate Cancer
• A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe … Recruiting
  2023-508517-16-00 7 2024-11-10 Advanced Solid Tumors with a KRAS p.G12C Mutation
• Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- … Recruiting
  2023-509292-17-00 4 2024-11-08 primary high-risk lobular breast cancer
• LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Pa … Recruiting
  2023-507178-41-00 9 2024-11-07 Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re … Recruiting
  2022-502972-22-00 5 2024-10-31 Clostridioides difficile infection.
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• not applicable Recruiting
  2023-508953-16-00 4 2024-10-25 Newly diagnosed high grade glioma (HGG) including diffuse intrinsic po
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or … Recruiting
  2023-507899-47-00 4 2024-10-22 Cytologic or molecular relapsed/refractory CD38 positive T-cell acute
• A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi … Recruiting
  2023-509851-15-00 5 2024-10-22 Colon cancer
• A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO … Recruiting
  2023-508760-29-00 5 2024-10-21 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 10 2024-10-09 HLA-A2 negative metastatic uveal melanoma
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting
  2023-508817-18-00 5 2024-10-08 Perennial Allergic Rhinitis (PAR)
• A Long-term Follow-up Study of Participants who Received INZ-701 in a previous clinical study Recruiting
  2024-512715-42-00 4 2024-10-08 Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron … Recruiting
  2023-508338-33-00 5 2024-10-01 Chronic Inflammatory Demyelinating Polyneuropathy
• Maintenance of durvalumab and olaparib after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive ext … Recruiting
  2024-512373-27-00 4 2024-09-30 Advanced/inoperable or metastatic small-cell lung cancer
• A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis Recruiting
  2023-508429-29-00 4 2024-09-26 Progressive Pulmonary Fibrosis
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508811-21-00 10 2024-09-25 Refractory Focal Onset Epilepsy
• A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu … Recruiting
  2023-510203-21-00 7 2024-09-24 locally advanced or metastatic non-small cell lung cancer (NSCLC) resi
• Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patient … Recruiting
  2024-512459-19-00 6 2024-09-13 Psoriatic arthritis

Showing 625–648 of 1,776 trials